L3VLUP
ProSign in

DNA in the 13F filings

Ginkgo Bioworks Holdings Inc · CUSIP 37611X209

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Quarter end
30 Sep 2025
the date the book describes
Filed
17 Nov 2025
latest of these filings; the earliest 31 Oct 2025
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
95
filed both Q2 2025 and Q3 2025; 4 listed it in both
Shares listed
7,131,149
combined, among listed positions
Reported value
$104m
combined, at the quarter end

Among the 95 comparable managers: 1 buyer (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +60,157.

Managers listing DNA in Q3 2025

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2025, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
Viking Global Investors LP3,577,128$52m0.14%Held014 Nov 2025 (the filing on sec.gov)
Baillie Gifford & Co3,235,254$47munder 0.1%Trimmed-40,79731 Oct 2025 (the filing on sec.gov)
Glenview Capital Management LLC149,379$2.2munder 0.1%Held014 Nov 2025 (the filing on sec.gov)
Caxton Associates LLP129,588$1.9munder 0.1%Newnew17 Nov 2025 (the filing on sec.gov)
PDT Partners LLC39,800$580kunder 0.1%Trimmed-28,63417 Nov 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2025 to Q3 2025, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

0246Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
DNA by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20245$62m50
Q4 20244$72m13
Q1 20254$43m11
Q2 20254$80m03
Q3 20255$104m12
Q4 20254$52m167
Q1 20262$37m916
Q2 20263$61m1110

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

DNA and GILD →DNA and AMGN →DNA and ARGX →Choose a stock to compare with DNA →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own DNA, latest filings →Back to the 13F Explorer →